J. Kofler

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study

I. Wolf, S. Pilz, E. Richtig, 2018, PloS one.

Ocular toxicity due to Trametinib and Dabrafenib

Y. El-Shabrawi, Michael Neumayer, S. Sarny, 2017, BMC Ophthalmology.

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

E. Richtig, O. Michielin, C. Hoeller, 2021, Journal for ImmunoTherapy of Cancer.

Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland

E. Richtig, O. Michielin, C. Hoeller, 2019, Annals of Oncology.

Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)—Phase II data covering impact of concomitant haematological malignancies

E. Richtig, V. Nguyen, M. Laimer, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Dabrafenib plus trametinib in unselected advanced BRAF V600–mut melanoma: a non-interventional, multicenter, prospective trial

E. Richtig, C. Hoeller, P. Koelblinger, 2023, Melanoma research.